What is the role of platinum agents in the treatment of metastatic breast cancer in patients with BRCA mutations?
Answer from: Medical Oncologist at Academic Institution
The TNT study compared taxanes versus carboplatin in triple negative breast cancer and did not show a difference in response rate. However, amongst BRCA germline mutation carriers there was a significantly higher response rate amongst women with BRCA mutations. Therefore, platinums are good options ...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
In patients with BRCA mutations, the TNT trial does show benefit/ I would consider these agents in patients with BRCA mutations.